{"nctId":"NCT02829957","briefTitle":"RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding","startDateStruct":{"date":"2016-09"},"conditions":["Venous Thromboembolism","Menstruation"],"count":19,"armGroups":[{"label":"Rivaroxaban","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rivaroxaban"]},{"label":"Apixaban","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Apixaban"]}],"interventions":[{"name":"Apixaban","otherNames":["Eliquis"]},{"name":"Rivaroxaban","otherNames":["Xarelto"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-pregnant women, age 18-50\n\n  * For study purposes, evidence of negative pregnancy is accounted for by the treating physician's initiation of treatment with oral anticoagulants\n* Objectively diagnosed VTE or atrial fibrillation/flutter\n* Patient reported active menstruation - does not apply to women who were recently pregnant\n* Clinical plan and patient agreement to treat with oral anticoagulation for 3 months or longer\n* Patients must have a working telephone\n\nExclusion Criteria:\n\n* Package insert exclusions for Eliquis (Apixban) or Xarelto (Rivaroxaban): \\[active pathological bleeding or severe hypersensitivity reaction to XARELTO or ELIQUIS (e.g., anaphylactic reactions)\\]\n* Plan to become pregnant in the next three months.\n* Concomitant prescribed use of aspirin or thienopyridenes or other platelet inhibiting drugs\n* Plan for surgical hysterectomy or endometrial ablation\n* Known uterine cancer\n* Von Willebrand's disease, or hemophilia\n* Known coagulopathy from liver disease\n* Conditions likely to preclude adherence to study procedures: Active intravenous drug use, known alcoholism, homelessness, or uncontrolled psychiatric illness.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PBAC Scores","description":"Measure Description: A PBAC Score of \\< 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows;\n\nTowels\n\n* 1 point for each lightly stained towel\n* 5 points or each moderately soiled towel\n* 20 points if the towel is completely saturated with blood\n\nTampons\n\n* 1 point for each lightly stained tampon\n* 5 points for each moderately soiled tampon\n* 10 points if the tampon is completely saturated with blood\n\nClots\n\n* 1 point for small clots\n* 5 points for large clots","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Planned Drug Administration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients That Held Drug for Menorrhagia","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Major Hemorrhage","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Venous Thromboembolism (VTE)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Crossed Over to Another Anticoagulant","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Relevant Non-major Bleeding","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Hemoglobin Concentration","description":"Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"13.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Physical Component Summary of Standard From 36","description":"The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"45.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":["PBAC > 100","Crossover to another anticoagulant","Anticoagulant discontinued for more than 48 hours","Worsening DVT","Bleeding that causes unplanned visit to a healthcare provider"]}}}